Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia

QR Code

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia

ABSTRACT Background ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse‐risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria. The therapeutic and prognostic impacts of hypomethylating agents (HMAs) an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yiming Cai, Jingwen Rui, Zhengwen Ding, Judan Xie, Zhou Jin, Jinyan Xiao, Yang Xu
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Series:	Cancer Medicine
Subjects:	acute myeloid leukemia ASXL1 hypomethylating agents venetoclax
Online Access:	https://doi.org/10.1002/cam4.71037
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study
by: Ji-Xin Tian, et al.
Published: (2025-07-01)

Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01)

Increase in serum IL-4 in response to venetoclax therapy in xenograft models of acute myeloid leukaemia
by: D. A. Bogdanova, et al.
Published: (2024-07-01)

Treatment of elderly patients with acute myeloid leukemia: personal experience
by: L. T. Shimanovskaya, et al.
Published: (2024-12-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Case report: A young woman with acute peri‑myocarditis and acute myeloid leukaemia with myelodysplasia-related changes
by: Zsolt Szakács, et al.
Published: (2025-01-01)

ASXL2 Modulates Chromatin Remodeling to Direct Osteogenesis and Multiple Cell Fate in hPDLSCs
by: Tianle Yang, et al.
Published: (2025-10-01)

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
by: Seiichi Okabe, et al.
Published: (2025-06-01)

Asxl1 regulates optic cup development through interaction with Lhx2 and epigenetic modulation of Wnt signaling
by: Seungtae Moon, et al.
Published: (2025-12-01)

First case report: near early T-cell precursor acute lymphoblastic leukemia with plasmacytoid dendritic cell proliferation effectively treated with Venetoclax plus HAG regimen
by: Jiongping Han, et al.
Published: (2025-12-01)

Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications
by: Wojciech Szlasa, et al.
Published: (2025-06-01)

Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations
by: Jie Yang, et al.
Published: (2025-09-01)

Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome Treatment
by: Sofia Brites Alves, et al.
Published: (2025-05-01)

Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice
by: E. A. Dmitrieva, et al.
Published: (2024-09-01)

Effect of the reverse transcriptase inhibitor efavirenz on 5-azacytidine-induced LINE1 long interspersed repeat expression and genetic instability in acute myeloid leukemia cells
by: Kh. M. Magomedova, et al.
Published: (2025-06-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
by: I. V. Cherkashina, et al.
Published: (2025-03-01)

Association of Pretreatment Serum Indirect Bilirubin Levels With Prognostic and Therapeutic Value in Patients With Newly Diagnosed Acute Myeloid Leukemia
by: Chunfang Kong, et al.
Published: (2025-02-01)

Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis
by: T. N. Subbotina, et al.
Published: (2023-03-01)

Effective venetoclax treatment for indolent T-cell lymphoma of the gastrointestinal tract: a case report and literature review
by: Ji-Mo Jian, et al.
Published: (2025-07-01)

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong
by: Qiwen Fang, et al.
Published: (2025-07-01)

Using the Minor Variant Finder software to identify and quantify the allelic burden level of somatic mutations in oncohematologic diseases
by: T. N. Subbotina, et al.
Published: (2020-07-01)

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
by: Samuel J. Yates, et al.
Published: (2025-07-01)

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
by: E. V. Morozova, et al.
Published: (2022-11-01)

Targeted therapy of newly diagnosed <i>FLT3</i>-mutated acute myeloid leukemia. A single-center ambispective cohort study
by: N. K. Pastukhov, et al.
Published: (2025-03-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Angiotensin I-converting enzyme gene plays a crucial role in the pathology of carcinomas in colorectal cancer
by: Keqian Zhang, et al.
Published: (2019-12-01)

Acute Myeloid Leukemia With Extramedullary Infiltration‐Gastric Myeloid Sarcoma: A Case Report and Literature Review
by: Cong Ding, et al.
Published: (2025-07-01)

Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)
by: M. Dargenio, et al.
Published: (2025-01-01)

ACUTE MYELOID LEUKEMIA PRESENTING AS ISOLATED MYELOID SARCOMA: A CASE REPORT
by: Elif Canpolat Hırfanoğlu, et al.
Published: (2025-07-01)

Myeloid sarcoma of the larynx as manifestation of the terminal stage of myeloproliferative disease
by: A. L. Kozhanov, et al.
Published: (2023-06-01)

Case Report: A familial hematological pedigree reveals VHL germline mutation as a principal predisposition factor with additional mutations modulating phenotypic heterogeneity
by: HuiLing Chen, et al.
Published: (2025-07-01)

Clinical characteristics and prognostic significance of extramedullary involvement in childhood acute myeloid leukemia
by: A. K. Ignatova, et al.
Published: (2021-04-01)

PECULIARITIES OF CHRONIC MYELOID LEUKEMIA INCIDENCE IN THE ALTAi krai
by: O. V. Efremova, et al.
Published: (2019-05-01)

Treatment of acute myeloid leukemia in children
by: A. V. Popa, et al.
Published: (2022-11-01)

CHRONIC MYELOID LEUKEMIA - CLINICAL AND IMMUNOLOGICAL PECULIARITIES IN ADULT PATIENTS
by: O. V. Smirnova
Published: (2012-05-01)

Priapismus as Leukostasis Manifestation in Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2020-12-01)

Priapismus as Leukostasis Manifestation in Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2020-12-01)